ARGENX SE (ARGX) research

ARGENX SE
ShareXLinkedInReddit
Sector
Biotechnology
Last price
$912.87
As of

Kresmion compiles this page from ARGX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

ARGENX SE (ARGX): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-29.

As of . Source: SEC EDGAR filings for ARGX. Method and limitations.

SHARE THIS CARD

Share the ARGX intelligence card

A branded snapshot of ARGX: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion ARGX intelligence card preview
Post to X
COMPANY DOSSIER

See the full ARGX dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for ARGX on one page. Preview it with sample data, then open it live with a free account.

Preview the ARGX dossier

Active signals for ARGX

FREE, NO ACCOUNT

Every signal on ARGX, as it fires

You are seeing 5 of 16 signals recorded on ARGX since 2026-06-10.

The five above landed across 2 days. The other 11 were recorded on 3 other days. 11 of the 16 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in ARGX (2026Q2)

Manager / securityMarket value% portfolioQoQ
CITADEL ADVISORS LLCCUSIP 04016X101 · 2026Q2$197.1M0.02%,
TWO SIGMA INVESTMENTS, LPCUSIP 04016X101 · 2026Q2$172.2M0.12%,
MILLENNIUM MANAGEMENT LLCCUSIP 04016X101 · 2026Q2$87.6M0.03%,
Point72 Asset Management, L.P.CUSIP 04016X101 · 2026Q2$37.1M0.04%,
D. E. Shaw & Co., Inc.CUSIP 04016X101 · 2026Q2$7.7M0.00%,
Bridgewater Associates, LPCUSIP 04016X101 · 2026Q2$1.8M0.01%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ARGX

ARGX against its peers

ARGX's operating margin of 48652.2% ranks in the 98th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.

MetricARGXPeer medianPercentilen
Revenue FY2.2M USD3.0B USD720
Revenue YoY-50.2%n/an/a2
Operating margin48652.2%23.2%9820
Net margin59650.7%16.7%9821
Return on equity17.6%14.4%6121
P / En/a26.9xn/a12

Peers (23): NTRA, MRNA, REGN, RVMD, ONC, BIIB, ALNY, VRTX, ROIV, RPRX, BNTX, INSM, INCY, UTHR, GMAB, GILD, AMGN, ASND, EXEL, NBIX, SMMT, BBIO, HALO. Left out: CSLLY (no annual filing), IVBXF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ARGX: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Follow ARGX on a live board

Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ARGX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the ARGX dossier